DOCSLIB.ORG

Storage Disorders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

GENETIC TESTING SOLUTIONS FOR: STORAGE DISORDERS EGL Genetics has nearly 50 years of genetic testing history built upon a strong academic foundation. Our expertise spans common and rare genetic disease testing, genomic variant interpretation, test development and research. As we have grown, we have evolved into a high-science and high-performing CLIA-certifi ed and CAP-accredited laboratory with over 1,100 test offerings across biochemical genetics, cytogenetics, and molecular genetic testing. COMPREHENSIVE OFFERINGS Lysosomal storage disorders and glycogen storage disorders (GSDs) with numerous subtypes, wide-ranging phenotypes and multi-organ and system involvement, which are often impossible to diagnose based on clinical features alone. EGL Genetics offers disease-specifi c, as well as, comprehensive biochemical and molecular testing to pinpoint the underlying cause of symptoms. Identifi cation of a causative genetic defect may provide information for prognosis and therapeutic intervention, and is required for carrier testing and early prenatal diagnosis. Lysosomal Storage Disorders • Mucopolysaccharidoses • Sphingolipidoses • Oligosaccharidoses Glycogen Storage Disorders ADVANTAGES OF PARTNERING WITH EGL GENETICS: • Board-certifi ed laboratory directors & genetic counselors to answer clinical and analytical questions • EGL Genetics’ oligosaccharide screening method provides additional information and more targeted follow-up pathways than traditional qualitative screens • Customizable NGS panels with add-on genes available upon request for no additional charge • Commitment to accurate sequence variant classifi cation: Free targeted parental testing for up to two variants of unknown signifi cance following proband only testing, plus complementary periodic variant review and report updates, variant database publicly available, and open data sharing via ClinVar • Competitive turnaround times for all testing with expedited testing when clinically indicated • Client portal for convenient result delivery • Billing experts & insurance specialists available to assist with pricing, payments, insurance coverage, prior-authorizations, and more 2460 Mountain Industrial Boulevard Tucker, GA 30084 egl-eurofi ns.com | 855-831-7447 STORAGE DISORDERS (BIOCHEMICAL GENETICS) DISEASE TEST CODE TEST NAME Storage Disorders LM Alpha-Mannosidosis: Alpha-Mannosidase Enzyme Activity, Leukocytes Storage Disorders LO Beta-Galactosidase Defi ciency: Beta-Galactosidase Activity, Leukocytes Storage Disorders LN Beta-Mannosidosis: Beta-Mannosidase Enzyme Activity, Leukocytes Storage Disorders LB Fabry Disease: Alpha-Galactosidase Enzyme Activity, Leukocytes Storage Disorders BGBCU Fabry Disease: Globotriaosylceramide (Gb3) Quantifi cation, Urine Storage Disorders BSAU Free Sialic Acid Quantifi cation, Urine Storage Disorders LP Fucosidosis: Alpha-Fucosidase Enzyme Activity, Leukocytes Storage Disorders AG Gaucher Disease: Angiotensin Converting Enzyme (ACE) Enzyme Activity, Serum Storage Disorders LG Gaucher Disease: Beta-Glucosidase Enzyme Activity, Leukocytes Storage Disorders BM Gaucher Disease: Biomarker Panel (ACE, CHITO, TRAP) Enzyme Activities, Serum Storage Disorders CZ Gaucher Disease: Chitotriosidase (CHITO) Enzyme Activity, Serum Storage Disorders TT Gaucher Disease: Tartrate Resistant Acid Phosphatase (TRAP) Enzyme Activity, Serum Storage Disorders LS Lysosomal Storage Disease: Panel Enzyme Activity (11 Enzymes), Leukocytes Storage Disorders BLSDS Lysosomal Storage Disorders: Urine Screening Storage Disorders LR Mucopolysaccharidosis Type I (Hurler Syndrome): Alpha-L-Iduronidase Enzyme Activity, Leukocytes Storage Disorders BMPS6 Mucopolysaccharidosis Type VI (Maroteaux Lamy Syndrome): Arylsulfatase B Enzyme Activity, Leukocytes Storage Disorders LQ Mucopolysaccharidosis Type VII (Sly Syndrome): Beta-Glucuronidase Enzyme Activity, Leukocytes Storage Disorders GA Mucopolysaccharidosis: Glycosaminoglycans (GAGs), Quantitative and Qualitative, Urine Storage Disorders DW Pompe Disease: Acid Alpha-Glucosidase Enzyme Activity, Leukocytes Storage Disorders HC Tay-Sachs Disease: Hex A Activity, WBC Storage Disorders OS Oligosaccharidosis and Congenital Disorders of Glycosylation: High resolution Oligosaccharide (Free Glycan) Profi le, Urine STORAGE DISORDERS (MOLECULAR GENETICS) DISEASE TEST CODE TEST NAME Glycogen Storage Disorders QL Glycogen Storage Disease V (McArdle Disease): PYGM Gene Sequencing Glycogen Storage Disorders QM Glycogen Storage Disease V (McArdle Disease): PYGM Gene Deletion/Duplication Glycogen Storage Disorders MM151 Glycogen Storage Disorders- Liver: Sequencing Panel 2460 Mountain Industrial Boulevard Tucker, GA 30084 egl-eurofi ns.com | 855-831-7447 STORAGE DISORDERS (MOLECULAR GENETICS) DISEASE TEST CODE TEST NAME Glycogen Storage Disorders MM152 Glycogen Storage Disorders- Muscle: Sequencing Panel Glycogen Storage Disorders MM150 Glycogen Storage Disorders: Comprehensive Sequencing Panel Glycogen Storage Disorders MD150 Glycogen Storage Disorders: Deletion/Duplication Panel Lysosomal Storage Disorders DG Fabry Disease: GLA Gene Sequencing Lysosomal Storage Disorders KX Fabry Disease: GLA Gene Deletion/Duplication Lysosomal Storage Disorders AK Gaucher Disease: GBA Gene Sequencing Lysosomal Storage Disorders DU GM1 Gangliosidosis: GLB1 Gene Sequencing Lysosomal Storage Disorders KZ GM1 Gangliosidosis: GLB1 Gene Deletion/Duplication Lysosomal Storage Disorders KR Krabbe Disease: GALC Gene Sequencing Lysosomal Storage Disorders LD Krabbe Disease: GALC Gene Deletion/Duplication Lysosomal Storage Disorders MM120 Lysosomal Storage Disorders: Sequencing Panel Lysosomal Storage Disorders MD120 Lysosomal Storage Disorders: Deletion/Duplication Panel Lysosomal Storage Disorders AV Metachromatic Leukodystrophy: ARSA Gene Sequencing Lysosomal Storage Disorders LI Metachromatic Leukodystrophy: ARSA Gene Deletion/Duplication Lysosomal Storage Disorders BO Mucopolysaccharidosis Type I: IDUA Gene Sequencing Lysosomal Storage Disorders LL Mucopolysaccharidosis Type I: IDUA Gene Deletion/Duplication Lysosomal Storage Disorders BQ Mucopolysaccharidosis Type II: IDS Gene Sequencing Lysosomal Storage Disorders LW Mucopolysaccharidosis Type II: IDS Gene Deletion/Duplication Lysosomal Storage Disorders FQ Mucopolysaccharidosis Type III: SGSH, GNS, HGSNAT, and NAGLU Gene Sequencing Panel Lysosomal Storage Disorders HV Mucopolysaccharidosis Type III: SGSH, GNS, HGSNAT, and NAGLU Gene Deletion/Duplication Panel Lysosomal Storage Disorders BY Niemann-Pick Disease (Type A and B): SMPD1 Gene Sequencing Lysosomal Storage Disorders ND Niemann-Pick Disease (Type A and B): SMPD1 Gene Deletion/Duplication Lysosomal Storage Disorders BZ Niemann-Pick Disease Type C: NPC1 and NPC2 Gene Sequencing Lysosomal Storage Disorders NE Niemann-Pick Disease Type C: NPC1 & NPC2 Gene Deletion/Duplication Lysosomal Storage Disorders AN Pompe Disease: GAA Gene Sequencing Lysosomal Storage Disorders NF Pompe Disease: GAA Gene Deletion/Duplication Lysosomal Storage Disorders DA Sandhoff Disease: HEXB Gene Sequencing Lysosomal Storage Disorders NG Sandhoff Disease: HEXB Gene Deletion/Duplication Lysosomal Storage Disorders DD Tay-Sachs Disease: HEXA Gene Sequencing Lysosomal Storage Disorders NH Tay-Sachs Disease: HEXA Gene Deletion/Duplication 2460 Mountain Industrial Boulevard Tucker, GA 30084 egl-eurofi ns.com | 855-831-7447 PARTNERING WITH EGL GENETICS EXPERIENCE MATTERS Nearly 50 years of comprehensive clinical genetic testing by board-certifi ed ABMGG laboratory directors reporting over 675,000 results- because experience matters. One of the fi rst laboratories in the genetics industry with exome sequencing, gene targeted array CGH, constitutional microarrays, congenital disorders of glycosylation, and rare disease testing. ORDER THE RIGHT GENETIC TESTS FOR YOUR PATIENTS EGL offers many subpanels as well as single gene testing to meet the individual needs of your patient. If your patient’s clinical presentation warrants more focused testing, EGL is happy to meet that need. To fi nd additional test offerings, including subpanels and specifi c genes, please visit our website (http://www.egl-eurofi ns.com) to search our comprehensive test menu. For assistance fi nding a particular gene or test, laboratory genetic counselor can be reached by: Phone: (470) 378-2200 Email: eglgc@egl-eurofi ns.com CONTRIBUTIONS TO THE GENETICS COMMUNITY | ClinVar and EmVClass EGL is committed to ensuring clients and their patients are kept as up-to-date as possible concerning the classifi cation of sequence variants. EGL was one of the fi rst clinical diagnostic laboratories to openly share data with the NCBI freely available public database ClinVar (>30,000 variants on >1,700 genes) and is also the only laboratory with a free online database (EmVClass), featuring a variant classifi cation search and report quest interface, which facilitates rapid interactive curation and reporting of variants. WE HAVE THE ANSWERS. Consolidate your testing needs with our industry-leading expertise in molecular genetics, cytogenetics, and biochemical genetic testing with a focus in rare disease testing. 2460 Mountain Industrial Boulevard Tucker, GA 30084 egl-eurofi ns.com | 855-831-7447.
Recommended publications
  • Epidemiology of Mucopolysaccharidoses Update

    Epidemiology of Mucopolysaccharidoses Update

    diagnostics Review Epidemiology of Mucopolysaccharidoses Update Betul Celik 1,2 , Saori C. Tomatsu 2 , Shunji Tomatsu 1 and Shaukat A. Khan 1,* 1 Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA; [email protected] (B.C.); [email protected] (S.T.) 2 Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA; [email protected] * Correspondence: [email protected]; Tel.: +302-298-7335; Fax: +302-651-6888 Abstract: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by a lysosomal enzyme deficiency or malfunction, which leads to the accumulation of glycosaminoglycans in tissues and organs. If not treated at an early stage, patients have various health problems, affecting their quality of life and life-span. Two therapeutic options for MPS are widely used in practice: enzyme replacement therapy and hematopoietic stem cell transplantation. However, early diagnosis of MPS is crucial, as treatment may be too late to reverse or ameliorate the disease progress. It has been noted that the prevalence of MPS and each subtype varies based on geographic regions and/or ethnic background. Each type of MPS is caused by a wide range of the mutational spectrum, mainly missense mutations. Some mutations were derived from the common founder effect. In the previous study, Khan et al. 2018 have reported the epidemiology of MPS from 22 countries and 16 regions. In this study, we aimed to update the prevalence of MPS across the world. We have collected and investigated 189 publications related to the prevalence of MPS via PubMed as of December 2020. In total, data from 33 countries and 23 regions were compiled and analyzed.
  • Carrier Screening for Genetic Diseases Policy Number: PG0442 ADVANTAGE | ELITE | HMO Last Review: 07/25/2019

    Carrier Screening for Genetic Diseases Policy Number: PG0442 ADVANTAGE | ELITE | HMO Last Review: 07/25/2019

    Carrier Screening for Genetic Diseases Policy Number: PG0442 ADVANTAGE | ELITE | HMO Last Review: 07/25/2019 INDIVIDUAL MARKETPLACE | PROMEDICA MEDICARE PLAN | PPO GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each individual policyholder contract. Paramount applies coding edits to all medical claims through coding logic software to evaluate the accuracy and adherence to accepted national standards. This guideline is solely for explaining correct procedure reporting and does not imply coverage and reimbursement. SCOPE X Professional X Facility DESCRIPTION Carrier screening is testing asymptomatic individuals to identify those who are heterozygous for serious or lethal single-gene disorders with the purpose of informing the risk of conceiving an affected child. Risk-based carrier screening is performed in individuals having an increased risk based on population carrier prevalence, and personal or family history. Conditions selected for screening can be based on ethnicities at high risk (e.g., Tay- Sachs disease in individuals of Ashkenazi Jewish descent) or may be pan-ethnic (e.g., screening for cystic fibrosis carriers). Ethnicity-based screening for some conditions has been offered for decades and, in some cases, has reduced the prevalence of diseases. While methods for carrier screening of conditions individually may have been onerous in the past, contemporary molecular techniques including next-generation sequencing allow simultaneously identifying carriers of a wide range of disorders efficiently and inexpensively. Expanded carrier screening (ECS) involves screening individuals or couples for disorders in many genes (up to 100s). The disorders included may also span a range of disease severity or phenotype. Arguments for ECS include potential issues in assessing ethnicity, ability to identify more potential conditions, efficiency, and cost.
  • Binding of Undamaged Double Stranded DNA to Vaccinia Virus

    Binding of Undamaged Double Stranded DNA to Vaccinia Virus

    Schormann et al. BMC Structural Biology (2015) 15:10 DOI 10.1186/s12900-015-0037-1 RESEARCH ARTICLE Open Access Binding of undamaged double stranded DNA to vaccinia virus uracil-DNA Glycosylase Norbert Schormann1, Surajit Banerjee2, Robert Ricciardi3 and Debasish Chattopadhyay1* Abstract Background: Uracil-DNA glycosylases are evolutionarily conserved DNA repair enzymes. However, vaccinia virus uracil-DNA glycosylase (known as D4), also serves as an intrinsic and essential component of the processive DNA polymerase complex during DNA replication. In this complex D4 binds to a unique poxvirus specific protein A20 which tethers it to the DNA polymerase. At the replication fork the DNA scanning and repair function of D4 is coupled with DNA replication. So far, DNA-binding to D4 has not been structurally characterized. Results: This manuscript describes the first structure of a DNA-complex of a uracil-DNA glycosylase from the poxvirus family. This also represents the first structure of a uracil DNA glycosylase in complex with an undamaged DNA. In the asymmetric unit two D4 subunits bind simultaneously to complementary strands of the DNA double helix. Each D4 subunit interacts mainly with the central region of one strand. DNA binds to the opposite side of the A20-binding surface on D4. Comparison of the present structure with the structure of uracil-containing DNA-bound human uracil-DNA glycosylase suggests that for DNA binding and uracil removal D4 employs a unique set of residues and motifs that are highly conserved within the poxvirus family but different in other organisms. Conclusion: The first structure of D4 bound to a truly non-specific undamaged double-stranded DNA suggests that initial binding of DNA may involve multiple non-specific interactions between the protein and the phosphate backbone.
  • Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma

    Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma

    cancers Article Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma 1, 1, 1 1 1 Lan Wang y, Anudeep Yekula y, Koushik Muralidharan , Julia L. Small , Zachary S. Rosh , Keiko M. Kang 1,2, Bob S. Carter 1,* and Leonora Balaj 1,* 1 Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA; [email protected] (L.W.); [email protected] (A.Y.); [email protected] (K.M.); [email protected] (J.L.S.); [email protected] (Z.S.R.); [email protected] (K.M.K.) 2 School of Medicine, University of California San Diego, San Diego, CA 92092, USA * Correspondence: [email protected] (B.S.C.); [email protected] (L.B.) These authors contributed equally. y Received: 11 March 2020; Accepted: 7 May 2020; Published: 13 May 2020 Abstract: Sequencing studies have provided novel insights into the heterogeneous molecular landscape of glioblastoma (GBM), unveiling a subset of patients with gene fusions. Tissue biopsy is highly invasive, limited by sampling frequency and incompletely representative of intra-tumor heterogeneity. Extracellular vesicle-based liquid biopsy provides a minimally invasive alternative to diagnose and monitor tumor-specific molecular aberrations in patient biofluids. Here, we used targeted RNA sequencing to screen GBM tissue and the matched plasma of patients (n = 9) for RNA fusion transcripts. We identified two novel fusion transcripts in GBM tissue and five novel fusions in the matched plasma of GBM patients. The fusion transcripts FGFR3-TACC3 and VTI1A-TCF7L2 were detected in both tissue and matched plasma.
  • Characterization of Α-L-Fucosidase and Other Digestive Hydrolases From

    Characterization of Α-L-Fucosidase and Other Digestive Hydrolases From

    Acta Tropica 141 (2015) 118–127 Contents lists available at ScienceDirect Acta Tropica journal homepage: www.elsevier.com/locate/actatropica Characterization of ␣-L-fucosidase and other digestive hydrolases from Biomphalaria glabrata Natalia N. Perrella a,b, Rebeca S. Cantinha c,d, Eliana Nakano c, Adriana R. Lopes a,∗ a Laboratory of Biochemistry and Biophysics—Instituto Butantan, São Paulo, Brazil b Programa de Pós Graduac¸ ão Interunidades em Biotecnologia PPIB, Universidade de São Paulo, São Paulo, SP, Brazil c Laboratory of Parasitology—Instituto Butantan, São Paulo, Brazil d Instituto de Pesquisas Energéticas e Nucleares, Universidade de São Paulo, São Paulo, SP, Brazil article info abstract Article history: Schistosoma mansoni is one of the major agents of the disease Schistosomiasis, which is one of the Received 10 February 2014 major global public health concerns. Biomphalaria glabrata is an obligate intermediate mollusc host of Received in revised form 3 July 2014 S. mansoni. Although the development of S. mansoni occurs in the snail hepatopancreas, studies that Accepted 12 August 2014 focus on this organ remain limited. In this study, we biochemically identified five distinct carbohy- Available online 16 September 2014 drases (amylase, maltase, ␣-glucosidase, trehalase, and ␣-L-fucosidase), lipases, and peptidases in the B. glabrata hepatopancreas and focused on the isolation and characterization of the activity of ␣-L- Keywords: fucosidase. The isolated ␣-L-fucosidase has a molecular mass of 141 kDa, an optimum pH of 5.8, and Hepatopancreas ␣ Enzymes is inhibited by Tris, fucose, and 1-deoxyfuconojirimycin. B. glabrata -L-fucosidase is an exoglycosidase ␮ ␣-L-Fucosidase that can hydrolyze the natural substrate fucoidan to fucose residues.
  • Low Levels of 18 Hexosaminidase a in Healthy Individuals with Apparent Deficiency of This Enzyme

    Low Levels of 18 Hexosaminidase a in Healthy Individuals with Apparent Deficiency of This Enzyme

    Am J Hum Genet 28:339-349, 1976 Low Levels of 18 Hexosaminidase A in Healthy Individuals with Apparent Deficiency of This Enzyme R. NAVON,1 B. GEIGER,2 Y. BEN YOSEPH,2 AND M. C. RATTAZZI3 INTRODUCTION The association between Tay-Sachs disease (TSD; GM,2 gangliosidosis type I) and generalized deficiency of /8 hexosaminidase A (hex A) activity with artificial sub- strates, first reported by Okada and O'Brien [1], is now well established. Using natural substrates, it has also been shown that tissues from patients with TSD cannot degrade GM2 ganglioside in vitro [2, 3] and that purified hex A, but ap- parently not purified /f hexosaminidase B (hex B), can hydrolyze GM2 ganglioside to a measurable extent [3, 4]. Thus, hex A deficiency is commonly believed to be the cause of the accumulation of GM2 ganglioside in patients with TSD. However, it has recently been reported that purified hex B can cleave GM2 ganglioside in vitro [5], raising the question of its participation in the catabolism of this glyco- lipid in vivo. In a recent publication [6], Navon et al. described a Jewish family in which four healthy adult individuals showed a severe deficiency of hex A activity. Using a heat inactivation method based on the differential thermal lability of hex A and hex B [7, 8], it was shown that, in these subjects, hex A activity with artificial substrates was comparable to that of patients with TSD [6]. Further studies em- ploying radioactive natural substrates, however, showed that leukocytes from these "variant" individuals were capable of hydrolysis of GA12 ganglioside in vitro [9].
  • The Counsyl Foresight™ Carrier Screen

    The Counsyl Foresight™ Carrier Screen

    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
  • Oral Ambroxol Increases Brain Glucocerebrosidase Activity in a Nonhuman Primate

    Oral Ambroxol Increases Brain Glucocerebrosidase Activity in a Nonhuman Primate

    Received: 17 November 2016 | Revised: 24 January 2017 | Accepted: 12 February 2017 DOI 10.1002/syn.21967 SHORT COMMUNICATION Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate Anna Migdalska-Richards1 | Wai Kin D. Ko2 | Qin Li2,3 | Erwan Bezard2,3,4,5 | Anthony H. V. Schapira1 1Department of Clinical Neurosciences, Institute of Neurology, University College Abstract London, NW3 2PF, United Kingdom Mutations in the glucocerebrosidase 1 (GBA1) gene are related to both Parkinson disease (PD) and 2Motac Neuroscience, Manchester, United Gaucher disease (GD). In both cases, the condition is associated with deficiency of glucocerebrosi- Kingdom dase (GCase), the enzyme encoded by GBA1. Ambroxol is a small molecule chaperone that has 3 Institute of Laboratory Animal Sciences, been shown in mice to cross the blood-brain barrier, increase GCase activity and reduce alpha- China Academy of Medical Sciences, Beijing synuclein protein levels. In this study, we analyze the effect of ambroxol treatment on GCase City, People’s Republic of China activity in healthy nonhuman primates. We show that daily administration of ambroxol results in 4University de Bordeaux, Institut des Maladies Neurodeg en eratives, UMR 5293, increased brain GCase activity. Our work further indicates that ambroxol should be investigated as Bordeaux F-33000, France a novel therapy for both PD and neuronopathic GD in humans. 5CNRS, Institut des Maladies Neurodeg en eratives, UMR 5293, Bordeaux F-33000, France KEYWORDS Correspondence ambroxol, glucocerebrosidase,
  • Glycoproteomics-Based Signatures for Tumor Subtyping and Clinical Outcome Prediction of High-Grade Serous Ovarian Cancer

    Glycoproteomics-Based Signatures for Tumor Subtyping and Clinical Outcome Prediction of High-Grade Serous Ovarian Cancer

    ARTICLE https://doi.org/10.1038/s41467-020-19976-3 OPEN Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer Jianbo Pan 1,2,3, Yingwei Hu1,3, Shisheng Sun 1,3, Lijun Chen1, Michael Schnaubelt1, David Clark1, ✉ Minghui Ao1, Zhen Zhang1, Daniel Chan1, Jiang Qian2 & Hui Zhang 1 1234567890():,; Inter-tumor heterogeneity is a result of genomic, transcriptional, translational, and post- translational molecular features. To investigate the roles of protein glycosylation in the heterogeneity of high-grade serous ovarian carcinoma (HGSC), we perform mass spectrometry-based glycoproteomic characterization of 119 TCGA HGSC tissues. Cluster analysis of intact glycoproteomic profiles delineates 3 major tumor clusters and 5 groups of intact glycopeptides. It also shows a strong relationship between N-glycan structures and tumor molecular subtypes, one example of which being the association of fucosylation with mesenchymal subtype. Further survival analysis reveals that intact glycopeptide signatures of mesenchymal subtype are associated with a poor clinical outcome of HGSC. In addition, we study the expression of mRNAs, proteins, glycosites, and intact glycopeptides, as well as the expression levels of glycosylation enzymes involved in glycoprotein biosynthesis pathways in each tumor. The results show that glycoprotein levels are mainly controlled by the expression of their individual proteins, and, furthermore, that the glycoprotein-modifying glycans cor- respond to the protein levels of glycosylation enzymes. The variation in glycan types further shows coordination to the tumor heterogeneity. Deeper understanding of the glycosylation process and glycosylation production in different subtypes of HGSC may provide important clues for precision medicine and tumor-targeted therapy.
  • Assessment of a Targeted Gene Panel for Identification of Genes Associated with Movement Disorders

    Assessment of a Targeted Gene Panel for Identification of Genes Associated with Movement Disorders

    Supplementary Online Content Montaut S, Tranchant C, Drouot N, et al; French Parkinson’s and Movement Disorders Consortium. Assessment of a targeted gene panel for identification of genes associated with movement disorders. JAMA Neurol. Published online June 18, 2018. doi:10.1001/jamaneurol.2018.1478 eMethods. Supplemental methods. eTable 1. Name, phenotype and inheritance of the genes included in the panel. eTable 2. Probable pathogenic variants identified in a cohort of 23 patients with cerebellar ataxia using WES analysis. eTable 3. Negative cases in a cohort of 23 patients with cerebellar ataxia studied using WES analysis. eTable 4. Variants of unknown significance (VUSs) identified in the cohort. eFigure 1. Examples of pedigrees of cases with identified causative variants. eFigure 2. Pedigrees suggesting mendelian inheritance in negative cases. eFigure 3. Examples of pedigrees of cases with identified VUSs. eResults. Supplemental results. This supplementary material has been provided by the authors to give readers additional information about their work. © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/26/2021 eMethods. Supplemental methods Patients selection In the multicentric, prospective study, patients were selected from 25 French, 1 Luxembourg and 1 Algerian tertiary MDs centers between September 2014 and July 2016. Inclusion criteria were patients (1) who had developed one or several chronic MDs (2) with an age of onset below 40 years and/or presence of a family history of MDs. Patients suffering from essential tremor, tic or Gilles de la Tourette syndrome, pure cerebellar ataxia or with clinical/paraclinical findings suggestive of an acquired cause were excluded.
  • SUMF1 Enhances Sulfatase Activities in Vivo in Five Sulfatase Deficiencies

    SUMF1 Enhances Sulfatase Activities in Vivo in Five Sulfatase Deficiencies

    SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies Alessandro Fraldi, Alessandra Biffi, Alessia Lombardi, Ilaria Visigalli, Stefano Pepe, Carmine Settembre, Edoardo Nusco, Alberto Auricchio, Luigi Naldini, Andrea Ballabio, et al. To cite this version: Alessandro Fraldi, Alessandra Biffi, Alessia Lombardi, Ilaria Visigalli, Stefano Pepe, et al.. SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies. Biochemical Journal, Portland Press, 2007, 403 (2), pp.305-312. 10.1042/BJ20061783. hal-00478708 HAL Id: hal-00478708 https://hal.archives-ouvertes.fr/hal-00478708 Submitted on 30 Apr 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Biochemical Journal Immediate Publication. Published on 8 Jan 2007 as manuscript BJ20061783 SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies Alessandro Fraldi*1, Alessandra Biffi*2,3¥, Alessia Lombardi1, Ilaria Visigalli2, Stefano Pepe1, Carmine Settembre1, Edoardo Nusco1, Alberto Auricchio1, Luigi Naldini2,3, Andrea Ballabio1,4 and Maria Pia Cosma1¥ * These authors contribute equally to this work 1TIGEM, via P Castellino, 111, 80131 Naples, Italy 2San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), H. San Raffaele Scientific Institute, Milan 20132, Italy 3Vita Salute San Raffaele University Medical School, H.
  • Sphingolipids and Cell Signaling: Relationship Between Health and Disease in the Central Nervous System

    Sphingolipids and Cell Signaling: Relationship Between Health and Disease in the Central Nervous System

    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 6 April 2021 doi:10.20944/preprints202104.0161.v1 Review Sphingolipids and cell signaling: Relationship between health and disease in the central nervous system Andrés Felipe Leal1, Diego A. Suarez1,2, Olga Yaneth Echeverri-Peña1, Sonia Luz Albarracín3, Carlos Javier Alméciga-Díaz1*, Angela Johana Espejo-Mojica1* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C., 110231, Colombia; [email protected] (A.F.L.), [email protected] (D.A.S.), [email protected] (O.Y.E.P.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá D.C., Colombia; [email protected] (D.A.S.) 3 Nutrition and Biochemistry Department, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C., Colombia; [email protected] (S.L.A.) * Correspondence: [email protected]; Tel.: +57-1-3208320 (Ext 4140) (C.J.A-D.). [email protected]; Tel.: +57-1-3208320 (Ext 4099) (A.J.E.M.) Abstract Sphingolipids are lipids derived from an 18-carbons unsaturated amino alcohol, the sphingosine. Ceramide, sphingomyelins, sphingosine-1-phosphates, gangliosides and globosides, are part of this group of lipids that participate in important cellular roles such as structural part of plasmatic and organelle membranes maintaining their function and integrity, cell signaling response, cell growth, cell cycle, cell death, inflammation, cell migration and differentiation, autophagy, angiogenesis, immune system. The metabolism of these lipids involves a broad and complex network of reactions that convert one lipid into others through different specialized enzymes. Impairment of sphingolipids metabolism has been associated with several disorders, from several lysosomal storage diseases, known as sphingolipidoses, to polygenic diseases such as diabetes and Parkinson and Alzheimer diseases.